Orthopaedics specialists BioMedical Enterprises (BME) has received the US Food and Drug Administration (FDA) approval for its upgraded HammerLock Nitinol intramedullary fixation system indicated for hammer toe deformities.
Made up of shape memory alloy Nitinol, the HammerLock is the most advanced intramedullary implant system for hammer toe fusions.
The company has enhanced the design of the HammerLock and the upgraded device now features a linear body that results in a greater bone fusion area at the joint interface, enhanced flexibility in positioning and easier reduction.
In addition, the Squeeze-Tab retention system further simplifies the insertion process of the HammerLock system.
In October 2010, the company launched the HammerLock intramedullary nitinol fixation system for use in the correction of hammer toes. The device stabilises the proximal joint of the toe without the need for exposed wires.
The HammerLock initially featured a flat body design that resists rotation, barbs to provide secure fixation and high-strength. The barbs maintain compression while reducing the stress on cortical walls.
In addition, the patent-pending tabbed HammerBlock Insertion System allows for fast, precise and no-touch insertion of the HammerLock implant.
The HammerLock has been designed to change shape when exposed to body heat.
BME president and CEO Keith M Peeples said: "This new design demonstrates our commitment to both developing new products and improving our existing lines."
BME surgeon consultant Dr Todd Stewart said: "This offers the surgeon easier insertion, prevents gapping at the arthrodesis site, and the new tab has just the right tension for keeping it on during reduction and for easy removal."
The upgraded BME HammerLock intramedullary fixation system will be available for clinical use shortly.